Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Orphan Designation
Sort By
Newest First
1 / 1
1 / 1
Granted Designation
Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
Merck & Co.
PR-M08-18-NI-037
Aug 10, 2018
